I wouldn't say back burner, but they clearly want to get the 52 week data finished so they can apply to the Alz foundation to fund p3. In the meantime, they need to get the Rett P2 trial funded and out the door. And epilepsy would be a great one to partner, get that P2 running....then the stock woudl get back to the teens. Missling has to show results.
No sign AD is on the back burner. To the contrary. But the company is clearly not putting all eggs in that basket, which is smart for many reasons (number one being they don't have to).